{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T05:00:20Z","timestamp":1791608420861,"version":"4.3.4"},"reference-count":45,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"vor","delay-in-days":608,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Laboratoire fran\u00e7ais du Fractionnement et des Biotechnologies"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1111\/jth.14928","type":"journal-article","created":{"date-parts":[[2020,5,23]],"date-time":"2020-05-23T16:39:59Z","timestamp":1590251999000},"page":"1922-1933","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Management of von Willebrand disease with a factor VIII\u2010poor von Willebrand factor concentrate: Results from a prospective observational post\u2010marketing study"],"prefix":"10.1016","volume":"18","author":[{"given":"Jenny","family":"Goudemand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Bridey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9gol\u00e8ne","family":"Claeyssens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Itzhar\u2010Ba\u00efkian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Harroche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Desprez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"N\u00e9grier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Chamouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Chambost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Henriet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Susen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Borel\u2010Derlon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/jth.14928_bb0010","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1056\/NEJMra1601561","article-title":"Von Willebrand\u2019s disease","volume":"375","author":"Leebeek","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1111\/jth.14928_bb0015","first-page":"94","article-title":"Von Willebrand\u2019s disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment","volume":"88","author":"Castaman","year":"2003","journal-title":"Haematologica"},{"key":"10.1111\/jth.14928_bb0020","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1111\/jth.12008","article-title":"von Willebrand factor: the old, the new and the unknown","volume":"10","author":"Lenting","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14928_bb0025","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1111\/j.1538-7836.2006.02146.x","article-title":"Working Party on von Willebrand Disease Classification. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor","volume":"4","author":"Sadler","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14928_bb0030","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1182\/blood.V69.2.454.454","article-title":"Epidemiological investigation of the prevalence of von Willebrand\u2019s disease","volume":"69","author":"Rodeghiero","year":"1987","journal-title":"Blood"},{"key":"10.1111\/jth.14928_bb0035","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000003038","article-title":"A laboratory phenotype\/genotype correlation of 1167 French patients from 670 families with von Willebrand disease: A new epidemiologic picture","volume":"95","author":"Veyradier","year":"2016","journal-title":"Medicine"},{"key":"10.1111\/jth.14928_bb0040","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1182\/blood.V79.12.3130.bloodjournal79123130","article-title":"Comparison of four virus inactivated plasma concentrates for treatment of severe von Willebrand disease: a cross\u2010over randomized trial","volume":"79","author":"Mannucci","year":"1992","journal-title":"Blood"},{"key":"10.1111\/jth.14928_bb0045","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1182\/blood.V83.10.3018.3018","article-title":"Proteolysis of von Willebrand factor in therapeutic plasma concentrates","volume":"83","author":"Mannucci","year":"1994","journal-title":"Blood"},{"key":"10.1111\/jth.14928_bb0050","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1365-2516.2004.00893.x","article-title":"A comparative in vitro evaluation of six von Willebrand factor concentrates","volume":"10","author":"Lethagen","year":"2004","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14928_bb0055","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1055\/s-2006-949668","article-title":"Comparative analysis and classification of von Willebrand factor\/factor VIII concentrates: impact on treatment of patients with von Willebrand disease","volume":"32","author":"Budde","year":"2006","journal-title":"Semin Thromb Hemost"},{"issue":"1","key":"10.1111\/jth.14928_bb0060","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/rth2.12166","article-title":"Evaluation of von Willebrand factor concentrates by platelet adhesion to collagen using an in vitro flow assay","volume":"3","author":"Riddell","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1111\/jth.14928_bb0065","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1365-2141.1992.tb08903.x","article-title":"Clinical and biological evaluation in von Willebrand's disease of a von Willebrand factor concentrate with low factor VIII activity","volume":"80","author":"Goudemand","year":"1992","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.14928_bb0070","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1046\/j.1365-2516.1998.0040s3048.x","article-title":"Clinical management of patients with von Willebrand\u2019s disease with a VHP vWF concentrate: the French experience","volume":"4","author":"Goudemand","year":"1998","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14928_bb0075","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1111\/j.1538-7836.2007.02562.x","article-title":"Treatment of severe von Willebrand disease with a high\u2010purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients","volume":"5","author":"Borel\u2010Derlon","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14928_bb0080","doi-asserted-by":"crossref","first-page":"e399","DOI":"10.1111\/hae.12498","article-title":"Thromboembolic incidence with transiently elevated levels of coagulation factors in patients with von Willebrand disease treated with VWF:FVIII concentrate during surgery","volume":"20","author":"Gill","year":"2014","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14928_bb0085","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/jth.14313","article-title":"Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery","volume":"17","author":"Peyvandi","year":"2019","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14928_bb0090","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMra040403","article-title":"Treatment of von Willebrand's Disease","volume":"351","author":"Mannucci","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.14928_bb0095","first-page":"1","article-title":"In vitro evaluation of a very\u2010high\u2010purity, solvent\/detergent\u2010treated, von Willebrand factor concentrate","volume":"61","author":"Mazurier","year":"1991","journal-title":"Vox Sang"},{"key":"10.1111\/jth.14928_bb0100","unstructured":"LFB, WILFACTIN, WILLFACT.Summary of Product Characteristics; https:\/\/www.medicines.org.uk\/emc\/product\/3706\/smpc. Accessed December 2019."},{"key":"10.1111\/jth.14928_bb0105","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1111\/j.1538-7836.2005.01435.x","article-title":"Pharmacokinetic studies on Wilfactin, a von Willebrand factor concentrate with a low factor VIII content treated with three virus\u2010inactivation\/removal methods","volume":"3","author":"Goudemand","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14928_bb0110","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.0042-9007.2004.00398.x","article-title":"In vitro study of a triple\u2010secured von Willebrand factor concentrate","volume":"86","author":"Mazurier","year":"2004","journal-title":"Vox Sang"},{"issue":"Suppl 1","key":"10.1111\/jth.14928_bb0115","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.thromres.2006.01.021","article-title":"Clinical experience of prophylactic treatment in von Willebrand disease","volume":"118","author":"Lethagen","year":"2006","journal-title":"Thromb Res"},{"key":"10.1111\/jth.14928_bb0120","unstructured":"Guideline on the Clinical Investigation of Human Plasma Derived von Willebrand factor Products (CPMP\/BPWG\/220\/02) London, 17 November 2005."},{"key":"10.1111\/jth.14928_bb0125","unstructured":"Guideline on the core SPC for human plasma derived von Willebrand factor (CPMP\/BPWG\/278\/02) London, 17 November 2005."},{"key":"10.1111\/jth.14928_bb0130","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1111\/jth.14315","article-title":"Fijnvandraat K, for the subcommittee on Factor VIII, Factor IX and Rare Bleeding Disorders. The definition, diagnosis and management of mild hemophilia A: communication from the SSC of the ISTH","volume":"16","author":"Makris","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14928_bb0135","doi-asserted-by":"crossref","unstructured":"Peyvandi F, Kouides P, Turecek PL, Dow E, Berntorp E. Evolution of replacement therapy for von Willebrand disease: from plasma fraction to recombinant von Willebrand factor. Blood Rev. doi: 10.1016\/j.blre.2019.04.001.","DOI":"10.1016\/j.blre.2019.04.001"},{"key":"10.1111\/jth.14928_bb0140","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood-2015-02-629873","article-title":"Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease","volume":"126","author":"Gill","year":"2015","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1111\/jth.14928_bb0145","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/j.thromres.2006.01.022","article-title":"Gastrointestinal bleeding in von Willebrand disease","volume":"118","author":"Makris","year":"2006","journal-title":"Thromb Res"},{"key":"10.1111\/jth.14928_bb0150","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/hae.12571","article-title":"The natural history of occult or angiodysplastic gastrointestinal bleeding in von Willebrand disease","volume":"21","author":"Makris","year":"2015","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14928_bb0155","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1160\/TH13-11-0952","article-title":"Gastrointestinal angiodysplasia and bleeding in von Willebrand disease","volume":"112","author":"Franchini","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.14928_bb0160","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1365-2516.2008.01901.x","article-title":"Treatment and prevention of acute bleedings in von Willebrand disease\u2013efficacy and safety of Wilate, a new generation von Willebrand factor\/factor VIII concentrate","volume":"15","author":"Berntorp","year":"2009","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14928_bb0165","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2516.2009.02088.x","article-title":"Efficacy and safety of highly purified, doubly virus\u2010inactivated VWF\/FVIII concentrates in inherited von Willebrand\u2019s disease: results of an Italian cohort study on 120 patients characterized by bleeding severity score","volume":"16","author":"Federici","year":"2010","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14928_bb0170","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1111\/hae.12497","article-title":"Wilate use in 47 children with von Willebrand disease: the North London paediatric haemophilia network experience","volume":"21","author":"Khair","year":"2015","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14928_bb0175","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0140-6736(95)90166-3","article-title":"Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep\u2010vein thrombosis","volume":"345","author":"Koster","year":"1995","journal-title":"Lancet"},{"key":"10.1111\/jth.14928_bb0180","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1056\/NEJM200008173430702","article-title":"High plasma levels of factor VIII and the risk of recurrent venous thromboembolism","volume":"343","author":"Kyrle","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.14928_bb0185","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1538-7836.2004.01033.x","article-title":"Elevated levels of FVIII: C within families are associated with an increased risk for venous and arterial thrombosis","volume":"3","author":"Bank","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14928_bb0190","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1111\/j.1365-2516.2012.02758.x","article-title":"Thrombotic adverse events to coagulation factor concentrates for treatment of patients with haemophilia and von Willebrand disease: a systematic review of prospective studies","volume":"18","author":"Coppola","year":"2012","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14928_bb0195","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.thromres.2014.12.017","article-title":"Clinical use of Haemate\u00ae P in von Willebrand disease: a 25\u2010year retrospective observational study","volume":"135","author":"Miesbach","year":"2015","journal-title":"Thromb Res"},{"key":"10.1111\/jth.14928_bb0200","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1055\/s-0037-1613225","article-title":"Venous thromboembolism in von Willebrand disease","volume":"88","author":"Mannucci","year":"2002","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.14928_bb0205","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s11239-008-0253-7","article-title":"Antithrombotic prophylaxis in patients with von Willebrand disease undergoing major surgery: when is it necessary?","volume":"28","author":"Franchini","year":"2009","journal-title":"J Thromb Thrombolysis"},{"key":"10.1111\/jth.14928_bb0210","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/MBC.0000000000000179","article-title":"Venous thrombosis in von Willebrand disease as observed in one centre and as reported in the literature","volume":"26","author":"Girolami","year":"2015","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1111\/jth.14928_bb0215","first-page":"117","article-title":"Italian Association of Haemophilia Centres. Evidence\u2010based recommendations on the treatment of von Willebrand disease in Italy","volume":"7","author":"Mannucci","year":"2009","journal-title":"Blood Transfus"},{"key":"10.1111\/jth.14928_bb0220","doi-asserted-by":"crossref","first-page":"667","DOI":"10.3324\/haematol.2012.077263","article-title":"European Group on von Willebrand Disease. Principles of care for the diagnosis and treatment of von Willebrand disease","volume":"98","author":"Castaman","year":"2013","journal-title":"Haematologica"},{"key":"10.1111\/jth.14928_bb0225","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2516.2007.01643.x","article-title":"von Willebrand disease (VWD): evidence based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA)","volume":"14","author":"Nichols","year":"2008","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14928_bb0230","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1182\/bloodadvances.2019000368","article-title":"New therapies for von Willebrand disease","volume":"3","author":"Mannucci","year":"2019","journal-title":"Blood Adv"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.14928","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.14928","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jth.14928","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622016245?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622016245?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.14928","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:29:10Z","timestamp":1761535750000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622016245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":45,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S1538783622016245"],"URL":"https:\/\/doi.org\/10.1111\/jth.14928","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of von Willebrand disease with a factor VIII\u2010poor von Willebrand factor concentrate: Results from a prospective observational post\u2010marketing study","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.14928","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2020 The Authors. Journal of Thrombosis and Haemostasis published by ELSEVIER INC. on behalf of International Society on Thrombosis and Haemostasis","name":"copyright","label":"Copyright"}]}}